Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

The insulin-like growth factor system and its receptors: A potential novel anticancer target

Authors Colin R. Lindsay, T R Jeffry Evans

Published 5 December 2008 Volume 2008:2(4) Pages 855—864


Review by Single-blind

Peer reviewer comments 3

Colin R. Lindsay1, T R Jeffry Evans1,2

1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 2University of Glasgow, CR-UK Beatson Laboratories, Garscube Estate, Glasgow, United Kingdom

Abstract: The current generation of novel anticancer therapies that are in preclinical and clinical development are based on exploiting our increasing understanding of the molecular and cellular basis of cancer development and progression. Accelerated rates of cell division and proliferation have been postulated to predispose to the development of malignant disease. The insulin-like growth factor (IGF) signaling system has an important physiological role in regulating cellular proliferation and apoptosis. This function has led to considerable interest in its relevance to neoplasia over the last decade. In this review, we give an overview of the IGF system physiology, discuss the epidemiological significance of IGF signaling and neoplasia, and review the preclinical and clinical studies in targeting IGF receptors as cancer therapies.

Keywords: insulin, growth factor, IGF-1, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Waiting lists in coronary artery bypass graft patients and role of coronary angiography: the Apulian experience

Ciccone MM, Aquilino A, Frasso G, Avolio F, Contegiacomo B, Graps E, Cortese F, Dentamaro I, Petrarolo V, Salvante D, Salvatore A, Caldarola P, Scicchitano P, Bux F

Clinical Audit 2013, 5:49-55

Published Date: 14 May 2013

Type 2 diabetes in a central Indian population: association with PPARG2 P121A allele but not ENPP1 K121Q

Tripathi AK, Shukla S, Dwivedi MK, Tripathi JK, Chauhan UK, Indurkar M, Singh S

Advances in Genomics and Genetics 2013, 3:1-9

Published Date: 4 April 2013

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Richard Quek, Suzanne George

Biologics: Targets and Therapy 2010, 4:19-31

Published Date: 3 February 2010

Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy

Bryan A Faller, Barbara Burtness

Biologics: Targets and Therapy 2009, 3:419-428

Published Date: 14 September 2009

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

Judith E Karp, Jeffrey E Lancet

Biologics: Targets and Therapy 2008, 2:491-500

Published Date: 12 September 2008

The antidiabetic effects of a dry powder of dietary vegetable and fruit mixtures in diabetic db/db mice

Chung-Man Yeung, Yi Tan, Sidney Tam, Liwei Lu, King-Hung Ko, et al

Biologics: Targets and Therapy 2008, 2:571-576

Published Date: 12 September 2008

Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition

Bostjan Humar, Les McNoe, Anita Dunbier, Rosemary Heathcott, Antony W Braithwaite, Anthony E Reeve

Biologics: Targets and Therapy 2008, 2:329-337

Published Date: 6 June 2008